Skip to content
Tech News
← Back to articles

AstraZeneca Enters Exclusive License Deal for Lung Cancer Drug Zegfrovy for Up to $1.5 Billion

2026-07-14 | original
read original more articles

AstraZeneca entered into an exclusive global license agreement with China’s Dizal Pharmaceutical for the lung cancer treatment.

Explore topics: agreement agreement china astrazeneca astrazeneca entered cancer
Related:
AstraZeneca Enters Exclusive License Deal For Lung Cancer Drug Zegfrovy For Up to $1.5 Billion
Could this mysterious disappearing organ hold the key to longevity?
Sam Neill has died
Reed Jobs would rather talk about curing cancer than his last name
Apple commits $30 billion to Broadcom for U.S. chipmaking push

© 2026 GoKawiil

About | Editorial Policy | Contact